Nov 23 (Reuters) - Cyclopharm Ltd (CYC)
- Received special protocol assessment (spa ) agreement1 from United States Food And Drug Administration
- Received special protocol assessment agreement1 for patient trials of its technegas product, to be known as cyc009
- Approval process remains on track for completion by mid2018 at a cost of less than $7 million usd
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
0.045(4.52%) |
Mkt cap ! $115.5M | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.06 | $1.00 | $35.35K | 34.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 658 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 2683 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| CYC (ASX) Chart |